Literature DB >> 444398

Distribution and tumour cytotoxicity of the radiosensitizer misonidazole (Ro-07-0582) in C57 mice.

J E Pedersen, M R Smith, R D Bugden, M J Peckham.   

Abstract

The distribution and clearance of misonidazole (MIS = Ro-07-0582) were studied in C57 mouse tissues and in transplants of Lewis lung tumour. The half life of the drug in blood after a dose of 1 mg/g i.p. was 3 h. Some tissues, such as liver, were found to have consistently low MIS levels, and this was found to be due to degradation of the drug after removal of the tissues from the host. The in vivo cytotoxicity of MIS to Lewis lung tumour cells was studied using an in-vitro colony assay. After half of the tumours had been irradiated with 10 Gy to kill most of the oxic cells, the mice received i.p. injections of MIS. To simulate the longer drug exposure of human tumour cells (due to the longer half life in man) a repeated injection regime was used in some mice. There was no significant cell kill after a single dose, but with a prolonged exposure to the drug in the multiply injected animals, cell survival was reduced to 50% of control in both the irradiated and unirradiated tumours. Since the hypoxic fraction of the unirradiated tumour is probably not more than 30%, it would appear that MIS is not selectively cytotoxic to hypoxic cells. However, MIS had a much greater cytotoxic effect upon hypoxic Lewis lung tumour cells in vitro, with very little or no effect on cells grown in air. This would support the theory that the presence of hypoxic cells is essential for the expression of MIS cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 444398      PMCID: PMC2009917          DOI: 10.1038/bjc.1979.76

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Hypoxic sensitizers: radiobiological studies at the cellular level.

Authors:  E J Hall; L Roizin-Towle
Journal:  Radiology       Date:  1975-11       Impact factor: 11.105

2.  Tumor size dependency in the radiation response of the Lewis lung carcinoma.

Authors:  W U Shipley; J A Stanley; G G Steel
Journal:  Cancer Res       Date:  1975-09       Impact factor: 12.701

3.  Sensitizing and toxicity properties of misonidazole and its derivatives.

Authors:  G F Whitmore; S Gulyas; A J Varghese
Journal:  Br J Cancer Suppl       Date:  1978-06

4.  Selective chemotherapy of noncycling cells in an in vitro tumor model.

Authors:  R M Sutherland
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

5.  Combined radiotherapy--chemotherapy of Lewis lung carcinoma.

Authors:  G G Steel; R P Hill; M J Peckham
Journal:  Int J Radiat Oncol Biol Phys       Date:  1978 Jan-Feb       Impact factor: 7.038

6.  Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography.

Authors:  P Workman; C J Little; T R Marten; A D Dale; R J Ruane; I R Flockhart; N M Bleehen
Journal:  J Chromatogr       Date:  1978-05-01

7.  Cytotoxic effects of the hypoxic cell radiosensitizer Ro 7-0582 to tumor cells in vivo.

Authors:  J M Brown
Journal:  Radiat Res       Date:  1977-12       Impact factor: 2.841

8.  The toxicity of the radiosensitizer misonidazole towards hypoxic cells in vitro: a model for mouse and man.

Authors:  I J Stratford; G E Adams
Journal:  Br J Radiol       Date:  1978-09       Impact factor: 3.039

9.  Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro.

Authors:  I J Stratford; G E Adams
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

10.  A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse.

Authors:  V D Courtenay
Journal:  Br J Cancer       Date:  1976-07       Impact factor: 7.640

  10 in total
  9 in total

1.  Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.

Authors:  P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.

Authors:  G Akel; P Benard; P Canal; G Soula
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.

Authors:  T C Stephens; V D Courtenay; J Mills; J H Peacock; C M Rose; D Spooner
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

4.  Is tumour radiosensitization by misonidazole a general phenomenon?

Authors:  J Denekamp; D G Hirst; F A Stewart; N H Terry
Journal:  Br J Cancer       Date:  1980-01       Impact factor: 7.640

5.  The penetration of misonidazole into a mature structural cartilage.

Authors:  A J Langler; R D Bugden; P Gibson
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

6.  Distribution of misonidazole in human tumours and normal tissues.

Authors:  D V Ash; M R Smith; R D Bugden
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640

7.  In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin.

Authors:  I F Tannock
Journal:  Br J Cancer       Date:  1980-12       Impact factor: 7.640

8.  The quantitative response of human tumours to radiation and misonidazole.

Authors:  D V Ash; M J Peckham; G G Steel
Journal:  Br J Cancer       Date:  1979-12       Impact factor: 7.640

9.  The effect of hypobaric hypoxia on misonidazole binding in normal and tumour-bearing mice.

Authors:  M P MacManus; A P Maxwell; W P Abram; J M Bridges
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.